Injected mesenchymal stromal cells (MSCs) create beneficial effects by modifying the environment around the affected joint. Inflammation is suppressed and immune mechanisms are modulated. The introduced cells signal and recruit the patient’s own mechanisms of repair and tissue regeneration in order to establish a long-term improvement which persists long after the injected cells are eliminated.
R&D is the cornerstone of MedXCell Science’s activity. Its first product candidate, ADIPOA is the result of more than 15 years of extensive R&D and rigorous scientific investigation. MedXCell Science is continuously carrying R&D projects to maintain its technological lead. Such projects include the creation of new generations of therapeutic products, the validation of biological activity tests and the improvement of industrial production methods.